- MEI Pharma Inc ( NASDAQ: MEIP) and also Infinity Pharmaceuticals Inc ( NASDAQ: INFI) have actually participated in a conclusive merging arrangement for an all-stock purchase developing a firm concentrating on 3 clinical-stage oncology medicine prospects.
- Infinity'' s Eganelisib is prepared to be assessed in mix with Merck & & Carbon Monoxide Inc (NYSE: MRK) Keytruda (pembrolizumab) in clients with head and also neck squamous cell cancer (HNSCC).
- Connected: Infinity Pharma Posts 52% Rise …
Complete tale offered on Benzinga.com
